Topical Imiquimod or Fluorouracil Therapy for Basal and Squamous Cell Carcinoma

Love, W. Elliot; Bernhard, Jeffrey D.; Bordeaux, Jeremy S.

doi:10.1001/archdermatol.2009.291

Cited by 252 publications

(232 citation statements)

References 41 publications

Supporting

Mentioning

218

Contrasting

Unclassified

Order By: Relevance

“…[96][97][98] Monotherapy with topical 5-FU, an antimetabolite, for superficial BCC is less well studied in welldesigned RCTs. 74,75 Typical regimens include twice-daily application for 3 to 6 weeks. Adverse events are similar to those with imiquimod and include erythema, swelling, crust, erosions, ulcers, and eschar.…”

Section: Topical Therapiesmentioning

confidence: 99%

See 1 more Smart Citation

Guidelines of care for the management of basal cell carcinoma

Baum¹,

Bordeaux²,

Brown³

et al. 2018

Journal of the American Academy of Dermatology

Self Cite

326

219

View full text Add to dashboard Cite

Basal cell carcinoma (BCC) is the most common form of human cancer, with a continually increasing annual incidence in the United States. When diagnosed early, the majority of BCCs are readily treated with office-based therapy, which is highly curative. In these evidence-based guidelines of care, we provide recommendations for the management of patients with BCC, as well as an in-depth review of the best available literature in support of these recommendations. We discuss biopsy techniques for a clinically suspicious lesion and offer recommendations for the histopathologic interpretation of BCC. In the absence of a formal staging system, the best available stratification based on risk for recurrence is reviewed. With regard to treatment, we provide recommendations on treatment modalities along a broad therapeutic spectrum, ranging from topical agents and superficially destructive modalities to surgical techniques and systemic therapy. Finally, we review the available literature and provide recommendations on prevention and the most appropriate follow-up for patients in whom BCC has been diagnosed. ( J Am Acad Dermatol

show abstract

Section: Topical Therapiesmentioning

confidence: 99%

“…This review also noted that 97% and 100% of patients treated with these topical medications for skin cancer, respectively, experienced at least 1 adverse event. 75 …”

Section: Topical Therapiesmentioning

confidence: 99%

Guidelines of care for the management of basal cell carcinoma

Baum¹,

Bordeaux²,

Brown³

et al. 2018

Journal of the American Academy of Dermatology

Self Cite

326

219

View full text Add to dashboard Cite

show abstract

“…Aspirin or acetylsalicylic acid -the oldest NSAIDs in use-may capture some special attention, since it has been demonstrated that this drug is not only capable of inhibiting COX enzymatic activity, but also of inhibiting the activity of IκB kinase-, inhibiting in this way the NF-κB pathway (Yin et al, 1998). It is of great interest to analyze another drug, imiquimod, recently approved by the US Food and Drug Administration (FDA) to be used topically in the treatment of human SCC and BCC (Love et al, 2009). This drug activates directly TLR-7 and TLR-8 and leads to the activation of NF-κB and AP-1 nuclear factors, resulting in the expression of pro-inflammatory cytokines, and probably -but not proven up to date-COX-2.…”

Section: Pharmacological Compounds In the Skin Cancer Treatmentmentioning

confidence: 99%

Cyclooxygenase-2 Overexpression in Non-Melanoma Skin Cancer: Molecular Pathways Involved as Targets for Prevention and Treatment

Maglio¹,

Paz²,

Maiten³

et al. 2011

Skin Cancers - Risk Factors, Prevention and Therapy

View full text Add to dashboard Cite

“…Chemicals such as topical 5-fluorouracil, imiquimod and chemical peeling are also used [14,15] . Such methods cause a local inflammatory process, which may cause discomfort to the patient by promoting itching, burning sensation and skin ulceration [16,17] . This symptoms may limit the technique use and reduce patients' adherence to treatment.…”

Section: Introductionmentioning

confidence: 99%